

Neurology Order Form

Fax completed form to: 833-908-1122



PATIENT INFORMATION			
Patient Name:		Date of Birth:	Referral Date:
Address:		City/State/Zip:	
Home Phone:	Cell Phone:	Work Phone:	
Secondary Contact:	Height:	Weight:	Male Female
Patient Diagnosis & ICD-10:			
Allergies:			
PROVIDER INFORMATION			
Physician Name:	Lic.#:	DEA #:	
Practice Name:	NPI#:		
Address:	City/State/Zip:		
Office Contact:	Phone:	Fax:	
Supervisory Physician (if applicable):			
PLEASE ATTACH			
Patient demographics & front/back copy of all insurance cards (prescription & medical) Recent office visit notes, history & physical, lab & pertinent procedure results Current medication list & list of prior medications tried and failed (with dates) Line access documentation/verification if applicable Quantitative serum Immunoglobulin lab results (<i>Uplizna only</i>) TB lab results within last 12 months (<i>Uplizna only</i>)		Vaccine status (any vaccination) and documentation of any recent vaccinations HBV lab results within last 12 months (<i>Uplizna only</i>) Date of diagnosis, current FVC%, ALSFRS-R score, and JourneyMate form (<i>Radicava only</i>) Anti-acetylcholine receptor (AChR) antibody positive results (<i>Vyvgart</i>) Letter of medical necessity if drug dosing or indication is outside of FDA guidelines	
NURSING & LAB ORDERS			
Nurse Orders: Nurse to provide assessment, teaching, lab draws, medication administration and vascular access device insertion and/or management per physician orders. Flush Orders: NaCl 0.9% - 5-10mL flush pre and post infusion and as needed Heparin - 10units/mL ---OR--- 100units/mL - 3-5mL flush after post-infusion NS flush if indicated to maintain line Lab Orders: Lab Date & Frequency:			
PRESCRIPTION ORDERS			
Anaphylaxis Kit: (Check all that apply)	Epinephrine 0.3mg IM as needed Diphenhydramine _____ mg IV as needed	Solu-cortef 250mg-500mg IV as needed NS Hydration 500 ml IV over 30 minutes as needed	Solu-Medrol 60mg - 125mg IV as needed Other _____
Pre-Medications: (Check all that apply)	Acetaminophen _____ mg PO _____ minutes prior to infusion Diphenhydramine _____ mg PO ---OR--- IV _____ minutes prior to infusion	Solu-Medrol _____ mg IV _____ minutes prior to infusion	Other _____
Supply Orders: All supplies for vascular access line care, drug administration kit(s), pump, and IV pole will be provided as necessary			
PRODUCT	PRESCRIPTION INFORMATION		REFILLS
Is this a first dose? Yes No If No, when was last dose given? _____ When is patient due for next dose? _____			
RADICAVA	Induction: 60mg IV infusion via gravity ---OR--- pump over 1 hour daily for 14 days followed by 14 day drug-free period		NONE
	Maintenance: 60mg IV infusion via gravity ---OR--- pump over 1 hour daily for 10 days out of 14 day period followed by 14 day drug-free periods		_____
UPLIZNA	Induction: 300mg IV infusion via gravity ---OR--- pump over approximately 90 minutes at 0 and 2 weeks and CBC lab testing every _____ months		NONE
	Maintenance: (starting 6 months from first infusion) 300mg IV infusion via gravity ---OR--- pump over approximately 90 minutes every 6 months		_____
VYEPTI	100mg IV infusion via gravity ---OR--- pump over approximately 30 minutes every 12 weeks		_____
	300mg IV infusion via gravity ---OR--- pump over approximately 30 minutes every 12 weeks		_____
VYVGART	10mg/kg IV infusion via gravity ---OR--- ---OR--- pump over at least 1 hour once every week for 4 weeks <i>*Up to max of 1200mg for patient weight of 120kg+ (Total volume is 125ml in NS solution)</i>		_____
	Administer additional treatment cycles every 50 days ---OR--- Prescriber to evaluate treatment cycle frequency after completion of initial treatment cycle According to the Package Insert: Administer subsequent treatment cycles based on clinical evaluation; the safety of initiating subsequent cycles sooner than 50 days from the start of the previous treatment cycle has not been established.		_____
VYVGART HYTRULO	1,008mg/11,200 units subcutaneous injection over approximately 30 to 90 seconds in cycles of once weekly injections for 4 weeks		_____
	Administer additional treatment cycles every 50 days ---OR--- Prescriber to evaluate treatment cycle frequency after completion of initial treatment cycle According to the Package Insert: Administer subsequent treatment cycles based on clinical evaluation; the safety of initiating subsequent cycles sooner than 50 days from the start of the previous treatment cycle has not been established.		_____
IG	Refer to Immunoglobulin Form		_____
SOLIRIS/ULTOMIRIS	Refer to Soliris or Ultomiris Order Form		_____
OTHER	_____		NONE
<i>By signing this form and utilizing our services, you are authorizing Amerita to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies.</i>			

Prescriber's Signature _____ Print Name _____ Date _____
 Dispense as Written

Prescriber's Signature _____ Print Name _____ Date _____
 Substitution Permitted

